Previous published results from the Know Your Tumor (KYT) program demonstrates the clinical utility of next generation sequencing to discover actionable alterations and improve pregression free survival (PFS) in pancreatic patients who received matched targeted therapy. The researchers further investgiate the impact of molecular profile-directed treatment on overall survival (OS). Among 1028 evaluable patients, 25% were identified to harbor actionable biomarkers. Highly actionable biomarkers discovered included homologous recombination DNA damage repair deficiencies (53.3%), PI3K/AKT/mTOR pathway alterations (19.8%) and BRAF oncogenic mutations/fusions (7.9%). Patients who received molecular-matched therapy based on these results experienced significant longer OS, 2.58 years, than those who only received unmatched therapy (molecular-matched vs only unmatched history(highly actionable): HR=0.42 [95% CI 0.26, 0.68]; molecular-matched vs patients without highly actionable findings: HR=0.34 [95% CI 0.22, 0.53]).These findings suggest that precision medicine could lead to improved outcomes in pancreatic cancer patients.
J Clin Oncol 37, 2019 (suppl; abstr 4138)